BioTuesdays

Cognition and FDA align on Phase 3 study of zervimesine in DLB

Cognition Logo

Cognition Therapeutics (NASDAQ: CGTX) has announced alignment with the FDA on key elements of a Phase 3 study of either 100 mg of oral zervimesine or placebo for nine months in mild-to-moderate dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints.

According to Cognition, the study will use a neuropsychiatric inventory that measures hallucinations and delusions as a primary endpoint.

In a statement, Lisa Ricciardi, president and CEO of Cognition, commented, “Over the course of the year, we have had collaborative discussions with FDA’s Divisions of Neurology and Psychiatry within the Office of Neuroscience. With FDA’s alignment on trial design, we are completing a protocol to support the planned registrational study in DLB, a disease with no approved treatments.”

POWERED BY

Stay Ahead in Healthcare & Life Sciences